[go: up one dir, main page]

CA2169840A1 - Nouveau produit pharmaceutique pour administration orale, renfermant de la progesterone et un polyethyleneglycol avec un excipient - Google Patents

Nouveau produit pharmaceutique pour administration orale, renfermant de la progesterone et un polyethyleneglycol avec un excipient

Info

Publication number
CA2169840A1
CA2169840A1 CA002169840A CA2169840A CA2169840A1 CA 2169840 A1 CA2169840 A1 CA 2169840A1 CA 002169840 A CA002169840 A CA 002169840A CA 2169840 A CA2169840 A CA 2169840A CA 2169840 A1 CA2169840 A1 CA 2169840A1
Authority
CA
Canada
Prior art keywords
starch
progesterone
pharmaceutical composition
composition according
estradiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002169840A
Other languages
English (en)
Inventor
Karen Susanne Gram
Annelise Jensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2169840A1 publication Critical patent/CA2169840A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention se rapporte à un produit pharmaceutique servant à l'administration par voie orale de la progestérone, ce produit pouvant contenir de manière appropriée un polyéthylène glycol ainsi qu'un autre excipient choisi dans le groupe comprenant un amidon, une cellulose, une pectine et un tragacanthe.
CA002169840A 1993-08-20 1994-08-19 Nouveau produit pharmaceutique pour administration orale, renfermant de la progesterone et un polyethyleneglycol avec un excipient Abandoned CA2169840A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK93950A DK95093D0 (da) 1993-08-20 1993-08-20 Farmaceutisk formulering indeholdende et hormon
DK0950/93 1993-08-20

Publications (1)

Publication Number Publication Date
CA2169840A1 true CA2169840A1 (fr) 1995-03-02

Family

ID=8099329

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002169840A Abandoned CA2169840A1 (fr) 1993-08-20 1994-08-19 Nouveau produit pharmaceutique pour administration orale, renfermant de la progesterone et un polyethyleneglycol avec un excipient

Country Status (17)

Country Link
EP (1) EP0789560A1 (fr)
JP (1) JPH09501682A (fr)
KR (1) KR960703570A (fr)
CN (1) CN1132478A (fr)
AU (1) AU7530594A (fr)
BR (1) BR9407306A (fr)
CA (1) CA2169840A1 (fr)
CZ (1) CZ42596A3 (fr)
DK (1) DK95093D0 (fr)
FI (1) FI960749A7 (fr)
HU (1) HUT74167A (fr)
LT (1) LT4043B (fr)
NO (1) NO960653L (fr)
NZ (1) NZ271617A (fr)
PL (1) PL313113A1 (fr)
SK (1) SK19396A3 (fr)
WO (1) WO1995005807A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772617B1 (fr) * 1997-12-19 2001-03-09 Besins Iscovesco Lab Comprime de progesterone et son procede de preparation
FR2775599B1 (fr) * 1998-03-09 2001-08-17 Besins Iscovesco Lab Composition pharmaceutique a base de progesterone naturelle de synthese et d'oestradiol et son procede de preparation
GB2339114B (en) * 1998-06-30 2003-03-05 Ericsson Telefon Ab L M Secure messaging in mobile telephones
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
RS50262B2 (sr) * 1999-08-31 2018-10-31 Bayer Pharma AG Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
FI20002768L (fi) * 2000-12-18 2002-06-19 Licentia Oy Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus
CN1622810A (zh) * 2002-03-14 2005-06-01 华生制药公司 孕酮口服药物传输系统
JP5207432B2 (ja) * 2003-04-29 2013-06-12 エム・エス・ディー・オス・ベー・フェー アンチ溶媒凝固プロセス
CA2603817C (fr) 2005-04-28 2013-03-19 Wyeth Compositions contenant du tanaproget micronise prepare par granulation humide
DE202007019049U1 (de) * 2007-11-05 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Verwendung eines Gestagens in Kombination mit einem Estrogen zur Prophylaxe der Laktoseintoleranz bei der oralen Kontrazeption
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US20110312928A1 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
BR112017027688A2 (pt) 2015-06-22 2018-09-04 Lipocine Inc Composições orais que contêm éster de 17- hidroxiprogesterona e métodos relacionados
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862311A (en) * 1971-04-12 1975-01-21 Ciba Geigy Corp Novel method of enhancing progestational endometrial proliferation with progesterone
FR2408345A1 (fr) 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
GB2091552A (en) 1980-09-09 1982-08-04 Carnrick G W Ltd Use of progesterone for the treatment of post-menopausal women
US4963540A (en) * 1986-04-16 1990-10-16 Maxson Wayne S Method for treatment of premenstrual syndrome
US5116619A (en) 1988-08-30 1992-05-26 Lee Roy Morgan Vaginal progesterone tablet
US5084277A (en) 1988-08-30 1992-01-28 Greco John C Vaginal progesterone tablet
AU5157590A (en) * 1989-02-06 1990-08-24 Abbott Laboratories Pharmaceutical compositions for oral administration
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions

Also Published As

Publication number Publication date
NZ271617A (en) 1996-11-26
FI960749L (fi) 1996-02-19
BR9407306A (pt) 1996-10-08
DK95093D0 (da) 1993-08-20
EP0789560A1 (fr) 1997-08-20
NO960653D0 (no) 1996-02-19
HUT74167A (en) 1996-11-28
KR960703570A (ko) 1996-08-31
CZ42596A3 (en) 1996-06-12
JPH09501682A (ja) 1997-02-18
PL313113A1 (en) 1996-06-10
LT96010A (fr) 1996-06-25
LT4043B (en) 1996-09-25
FI960749A0 (fi) 1996-02-19
FI960749A7 (fi) 1996-02-19
HU9600376D0 (en) 1996-04-29
WO1995005807A1 (fr) 1995-03-02
SK19396A3 (en) 1997-03-05
AU7530594A (en) 1995-03-21
NO960653L (no) 1996-02-19
CN1132478A (zh) 1996-10-02

Similar Documents

Publication Publication Date Title
CA2169840A1 (fr) Nouveau produit pharmaceutique pour administration orale, renfermant de la progesterone et un polyethyleneglycol avec un excipient
CA2470703C (fr) Produits pharmaceutiques oraux renfermant 17.beta.-estradiol-3-alcanoate inferieur, procede d'administration et de preparation associes
RU2479306C2 (ru) Фармацевтическая композиция, содержащая тетрагидрофолиевую кислоту
JPH04290830A (ja) 避妊薬処方物
JP2004533419A (ja) ホルモン補充療法
EP1990044A1 (fr) Compositions pharmaceutiques de mifepristone et leurs procédé de préparation
AU722355B2 (en) New hormonal medicaments and their use for the correction of oestrogenic deficiencies
JP2000515888A (ja) 経口避妊薬
AU747710B2 (en) Progestogen-antiprogestogen regimens
EP0322020A1 (fr) Unité de dosage pharmaceutique pour traiter les troubles climactériques et l'ostéoporose
RU2258512C2 (ru) Противозачаточное лекарственное средство на основе гестагена и эстрогена и способ его получения
JPH02174717A (ja) 多相避妊製剤
TW200306846A (en) Hormone replacement therapy
WO2023007312A1 (fr) Contraception orale à base de progestatif seul
NZ514895A (en) Use of the anti-progestagen ORG 33245 administrated intermittently with a daily dosage of a progestagen in combined therapy
HK1131917B (en) Pharmaceutical composition containing a tetrahydrofolic acid
HK1179165A (en) Pharmaceutical composition containing a tetrahydrofolic acid

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 19990819